Luminex Corporation Pre-Release of 2nd Quarter 2020 Revenue

On July 8, 2020 Luminex Corporation (Nasdaq: LMNX) reported 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019 (Press release, Luminex, JUL 8, 2020, View Source [SID1234561772]). Highlights include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Molecular Diagnostics revenue of approximately $65 million, up over 100% vs. Q2 2019
Sample-to-answer MDx revenue of approximately $30 million, up nearly 65% vs. Q2 2019
Non-automated MDx assay revenue of approximately $35 million, up nearly 150% vs. Q2 2019
Automated MDx assay revenue of approximately $26 million, up more than 55% vs. Q2 2019
170 sold or contracted sample-to-answer systems, the majority of which were ARIES Systems
Strong demand driven by pandemic-related sales across all Respiratory/COV-19 products
Licensed Technologies Group revenue of approximately $35 million, down 5% vs. Q2 2019
Placed approximately 210 xMAP systems
Partially affected by slowdown in research market
Flow Cytometry revenue of more than $7 million, down over 45% vs. Q2 2019
Up sequentially by approximately 10%
Continues to be significantly affected by slowdown in academic research
Had an additional $2 million of confirmed orders that were not able to be installed due to the COVID-19 pandemic
"We finished the quarter with record revenue of between $109 and $110 million," said Nachum "Homi" Shamir, President and CEO of Luminex. "With the EUA clearance of our IgG serology assay, we have expanded the breadth of our portfolio and believe that we are well positioned to continue to play a pivotal role in combating the COVID-19 pandemic. In addition, the remainder of our business continues to be healthy, and with xMAP INTELLIFLEX Systems now in our Partners’ hands, we are positioned to further strengthen our partnership business with this state-of-the-art platform."

The full financial results for the quarter, and any changes to 2020 guidance and/or provision thereof, will be discussed on our second quarter earnings call, currently scheduled for August 3, 2020.

PharmaCyte Biotech Successfully Completes Three-Month Stability Study

On July 8, 2020 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that it has successfully completed the three-month product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps and CypCaps passed all of the FDA-required tests (Press release, PharmaCyte Biotech, JUL 8, 2020, View Source [SID1234561757]). This is the final product that will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of the completed three-month stability study, "We are pleased to announce that our Cell-in-a-Box encapsulated cell product CypCaps has passed all of the FDA-required tests for the first three-months of a 24-month stability study. This is part of an ongoing study to determine the shelf life of the CypCaps final product that the FDA requires for all medical products. The data will be included in our IND. All future longer-term shelf life analyses, such as the next one at six months post-production, will be reported to the FDA but is not required for PharmaCyte to submit an IND."

As based in the ICH guidelines, regulatory agencies around the world, including the FDA, require a shelf-life determination for all medical products. Living products, like cell therapies such as CypCaps, as well as live vaccines etc., are particularly sensitive and more prone to inactivation over time, so it is especially important to determine the shelf-life for these products.

A battery of tests was performed on CypCaps that had been frozen post-production for three months of storage at -80C. Samples were thawed to show that the cells inside the CypCaps were still alive and functional as well as free of infectious agents. Some of these tests were performed by Austrianova (cell count, biological activity of the cells, capsule integrity, label integrity), whereas others (sterility, pH measurement) were performed by contract labs.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: View Source

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

On July 8, 2020 Thermo Fisher Scientific reported that it has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan (Press release, Thermo Fisher Scientific, JUL 8, 2020, View Source [SID1234561773]). The CDx will be leveraged to identify ROS1-positive non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with entrectinib (Rozlytrek). Approval by the MHLW would accelerate access to Chugai’s targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Entrectinib received MHLW approval in February 2020 to treat ROS1-positive NSCLC adult patients. Prior to that, the drug received accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2019 to treat ROS1-positive NSCLC adult patients, and both adult and pediatric patients with solid tumors that have NTRK gene fusions. ROS1 gene fusions are prevalent in 1-2 percent of NSCLC cases. It is one of 46 cancer-related biomarkers evaluated by the MHLW-approved version of Thermo Fisher’s Oncomine Dx Target Test. The MHLW previously approved the test as a CDx for four biomarkers – EGFR, ALK, ROS1 and BRAF – associated with 12 targeted therapies for NSCLC. The test was previously approved to identify ROS1-postitive patients for treatment with crizotinib in the U.S.

Oncomine Dx Target Test is currently reimbursed by government and commercial insurers in the U.S., Europe, Japan and South Korea, covering more than 550 million lives globally. Lung cancer is the leading cause of cancer deaths worldwide, and each year the disease causes more than 1.6 million deaths – more than breast, colon and prostate cancers combined. In Japan, lung cancer is the leading cause of cancer deaths in men, making up about 25 percent of all male cancer deaths in 2015.1

"Since receiving premarket approval for Oncomine Dx Target Test in 2017, Thermo Fisher has accelerated its endeavor to expand the use of comprehensive biomarker testing globally," said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher. "Our latest agreement underscores this commitment to build on the Oncomine Dx Target Test, which is still the first-and-only approved NGS companion diagnostic in Japan that is administered locally to expedite patient testing in the region."

Entry into a Material Definitive Agreement

On July 8, 2020, FibroGen China Anemia Holdings, Ltd., FibroGen (China) Medical Technology Development Co., Ltd. ("FibroGen Beijing"), and FibroGen International (Hong Kong) Limited (collectively, "FibroGen China") and AstraZeneca AB ("AstraZeneca", and together with FibroGen China, the "Parties") reported that entered into an amendment, effective July 1, 2020, to the Amended and Restated License, Development and Commercialization Agreement effective as of July 30, 2013 (the "China Agreement"), relating to the development and commercialization of roxadustat in China (the "Amendment") (Filing, 8-K, FibroGen, JUL 8, 2020, View Source [SID1234561813]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Amendment provides for the establishment of a jointly owned entity (the "Distribution Entity") that will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. FibroGen Beijing will continue to hold all of the regulatory licenses issued by China regulatory authorities and will continue to be primarily responsible for regulatory, clinical, manufacturing, medical affairs and pharmacovigilance.

While the responsibilities of the Parties under the China Agreement remain largely the same, and the Parties will continue to share equally in the economics resulting from roxadustat operations in China, certain changes are being made. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses are billed, and the collaboration has been adjusted to more fully account for the cost of manufacturing. AstraZeneca’s sales and marketing costs billed to the joint venture are now subject to an annual cap at a percentage of net sales, until they have been fully reimbursed for their costs, at which point AstraZeneca will invoice based on actual costs. FibroGen Beijing will now manufacture and supply commercial product to the joint venture, at a percentage of net sales and such percentage will be subject to a cap.

Once the Distribution Entity is fully operational, FibroGen will recognize revenue based on its sales to the Distribution Entity. AstraZeneca is expected to consolidate the Distribution Entity, and recognize revenue based on sales to customers. The Amendment better aligns the Parties’ interests and is expected to enable profitability for roxadustat commercialization in China at an earlier point in time.

In addition, AstraZeneca’s right to share in the economic benefits of the collaboration will largely continue to be deferred until certain measures of profitability have been met, but will no longer be subject to a minimum cash level at FibroGen Beijing.

Development costs will continue to be shared 50/50 between the Parties.

The Parties are concurrently amending the Amended and Restated License, Development and Commercialization Agreement for roxadustat for the U.S. and all other countries not previously licensed to Astellas Pharma, effective as of July 13, 2013 (such amendment, together with the Amendment, the "Amendments") to reflect minor changes in the governance structure under the China Agreement.

The foregoing description of the Amendments is not a complete description thereof, and is qualified in its entirety by reference to the full text of the Amendments, which will be filed with the Securities and Exchange Commission as exhibits to FibroGen, Inc.’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2020.

Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™

On July 8, 2020 Novocure (NASDAQ: NVCR) reported that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the first-line treatment of unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM), in combination with pemetrexed and platinum-based chemotherapy (Press release, NovoCure, JUL 8, 2020, View Source [SID1234561758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a disease with a poor prognosis, so being able to offer patients a therapy that results in excellent response rates with minimal toxicity is exciting," said Matthew T. Ballo, M.D., FACR, Professor and Chair, Department of Radiation Oncology, West Cancer Center & Research Institute in Germantown, Tennessee. "We as clinicians can have a big impact on our patients’ lives by making them aware of this important new technology."

"We are proud of the progress we have made in the last year in making Optune Lua accessible to patients," said Pritesh Shah, Novocure’s Chief Commercial Officer. "We continue to work diligently to expand the number of centers that can provide Tumor Treating Fields therapy to patients facing this devastating and aggressive disease."

Of the more than 50 certified centers, 28 are now offering Optune Lua to MPM patients. The remaining centers are in the process of completing all regulatory requirements.

For a complete list of centers where Optune can be prescribed, please visit OptuneLuaCenters.com.

About Optune Lua

Optune Lua is a noninvasive, antimitotic cancer treatment for MPM. Optune Lua delivers Tumor Treating Fields to the region of the tumor.

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells of a specific size. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with glioblastoma and in the U.S. for mesothelioma, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types – including some of the most aggressive forms of cancer.

Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Approved Indications

Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy.

Important Safety Information

Contraindications

Do not use Optune Lua in patients with implantable electronic medical devices such as pacemakers or implantable automatic defibrillators, etc. Use of Optune Lua together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure.

The most common (≥10%) adverse events involving Optune Lua in combination with chemotherapy were anemia, constipation, nausea, asthenia, chest pain, fatigue, medical device site reaction, pruritus, and cough.

Other potential adverse effects associated with the use of Optune Lua include: treatment related skin toxicity, allergic reaction to the plaster or to the gel, electrode overheating leading to pain and/or local skin burns, infections at sites of electrode contact with the skin, local warmth and tingling sensation beneath the electrodes, muscle twitching, medical device site reaction and skin breakdown/skin ulcer.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Do not prescribe Optune Lua for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.